Biogen Idec, Inc. (NASDAQ: BIIB) reported Q4 EPS of $1.51, $0.02 better than the analyst estimate of $1.49. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.29 billion.

Biogen Idec, Inc. sees FY2012 EPS of $6.10-$6.20, versus the consensus of $6.32.

For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.

Earnings Guidance Hot Guidance